Samsung Biologics Co., Ltd.: Business Overview, Financials & Competitive Analysis
Samsung Biologics Co., Ltd. scores 8/10 on the AskCyborg Cyborg Score (Strong). Samsung Biologics is a pure-play CDMO leader with strong revenue growth, expanding global capacity, and improving sustainability credentials, positioned to capture increasing demand in biologics manufacturing. With a market capitalization of $54.5B and trailing 12-month revenue of $3.9B, Samsung Biologics demonstrates substantial scale in the CDMO market. In.
What is Samsung Biologics Co., Ltd.'s industry? Samsung Biologics Co., Ltd. (samsungbiologics.com) operates in Contract Development and Manufacturing Organization (CDMO) / Biopharmaceutical Manufacturing. AskCyborg classifies Samsung Biologics Co., Ltd. under Contract Development and Manufacturing Organization (CDMO) / Biopharmaceutical Manufacturing in its company registry.
Samsung Biologics is a biopharmaceutical company engaged in drug development and manufacturing services, operating through two segments: Biopharmaceutical Development and Commercialization, and Contract Development an...
Cyborg Score thesis
Samsung Biologics is a pure-play CDMO leader with strong revenue growth, expanding global capacity, and improving sustainability...
Read the full analyst-debate transcript →Get the Latest Samsung Biologics Co., Ltd. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeSamsung Biologics Co., Ltd. Overview
Pro stress-test →Samsung Biologics is a biopharmaceutical company engaged in drug development and manufacturing services, operating through two segments: Biopharmaceutical Development and Commercialization, and Contract Development and Manufacturing Organization (CDMO). The company generates the majority of its revenue from the CDMO segment, positioning it as a leading CDMO offering end-to-end integrated services ranging from late discovery to commercial manufacturing.
Strategic Profile
Pro stress-test →Samsung Biologics recently completed the spin-off of Samsung Bioepis, reinforcing its strategic focus as a pure-play CDMO. With combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II, and 60,000 liters from an acquisition of a Maryland facility, the company leverages cutting-edge technologies to advance diverse modalities including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. The company received EcoVadis' Platinum Sustainability Rating in January 2026, placing it in the top one percent of companies evaluated globally.
Competitive Landscape
Pro stress-test →Samsung Biologics operates in the CDMO sector alongside competitors providing contract manufacturing, cell line development, and process development services for biopharmaceutical companies. The company competes on manufacturing capacity, technological capability, regulatory expertise, and geographic reach in a highly consolidated market dominated by specialized CDMOs and larger contract manufacturers.
Industry Context
Samsung Biologics Co., Ltd. operates in Contract Development and Manufacturing Organization (CDMO) / Biopharmaceutical Manufacturing.
Key facts
Founded: 2011 · Headquarters: Incheon, South Korea · Employees: 4,770 · Revenue: $3.9B (TTM) · Market cap: $54.5B